Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) received a $15 million milestone payment after the National Medical Products Administration of the People’s Republic of China approved its lotilaner ophthalmic solution, TP‑03. The approval was granted to Grand Pharmaceutical Group Limited, Tarsus’s exclusive partner for the Greater China region, and the payment is a direct result of this regulatory event.
The milestone is tied to the NMPA approval of TP‑03, marketed in the United States as XDEMVY, and is part of the agreement between Tarsus and Grand Pharma. The payment was contingent on both regulatory approval and patent issuance, both of which were achieved. The agreement also provides for additional milestone payments and tiered royalties that will be triggered by future regulatory milestones and sales thresholds in Greater China.
The $15 million infusion strengthens Tarsus’s cash position and supports its commercial expansion in a market that includes more than 40 million people affected by Demodex blepharitis. The payment also signals the company’s ability to secure international approvals and monetize its lotilaner platform beyond the U.S., creating a new revenue stream that complements the strong U.S. sales momentum of XDEMVY.
Tarsus’s U.S. commercial performance has been robust, with net product sales of $151.7 million in Q4 2025 and $451.4 million for the full year. The company has guided for 2026 net sales of $670–$700 million, while maintaining a balance sheet with more cash than debt. The China approval and milestone payment are expected to accelerate the company’s path to profitability, which is projected for 2027.
CEO Bobak Azamian said, “TP‑03 is once again the first and only therapy approved to address the root cause of Demodex blepharitis—marking a meaningful advance for the more than 40 million people in the region affected by this disease.” He added, “This approval underscores our commitment to bringing this much‑needed treatment to patients worldwide, and we look forward to supporting Grand Pharma as they prepare for launch.” Analysts have reaffirmed an Outperform rating and raised price targets, reflecting confidence in the company’s execution and the blockbuster potential of XDEMVY in international markets.
The milestone payment and China approval represent a significant step in Tarsus’s global expansion strategy, providing both immediate financial benefit and a foundation for future revenue growth through additional milestones and royalties in the Greater China region.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.